TW200621723A - Novel imidazolidine derivative and use thereof - Google Patents

Novel imidazolidine derivative and use thereof

Info

Publication number
TW200621723A
TW200621723A TW094131141A TW94131141A TW200621723A TW 200621723 A TW200621723 A TW 200621723A TW 094131141 A TW094131141 A TW 094131141A TW 94131141 A TW94131141 A TW 94131141A TW 200621723 A TW200621723 A TW 200621723A
Authority
TW
Taiwan
Prior art keywords
compound
independently
alkyl
formula
nrb
Prior art date
Application number
TW094131141A
Other languages
English (en)
Inventor
Kazutaka Tachibana
Haruhiko Sato
Masateru Ohta
Mitsuaki Nakamura
Takuya Shiraishi
Hitoshi Yoshino
Takashi Emura
Akie Honma
Etsuro Onuma
Hiromitsu Kawata
Kenji Taniguchi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of TW200621723A publication Critical patent/TW200621723A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW094131141A 2004-09-09 2005-09-09 Novel imidazolidine derivative and use thereof TW200621723A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004262888 2004-09-09

Publications (1)

Publication Number Publication Date
TW200621723A true TW200621723A (en) 2006-07-01

Family

ID=36036508

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094131141A TW200621723A (en) 2004-09-09 2005-09-09 Novel imidazolidine derivative and use thereof

Country Status (9)

Country Link
US (1) US8470829B2 (zh)
EP (1) EP1790640A4 (zh)
JP (1) JP4989227B2 (zh)
KR (1) KR20070106969A (zh)
CN (2) CN101676270A (zh)
AU (1) AU2005280908A1 (zh)
CA (1) CA2579886A1 (zh)
TW (1) TW200621723A (zh)
WO (1) WO2006028226A1 (zh)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078448A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
CA2550447A1 (en) 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
NZ550102A (en) 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
ATE541571T1 (de) * 2005-05-13 2012-02-15 Univ California Diarylhydantoin-verbindung
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
AU2013200746B2 (en) * 2005-05-13 2015-11-19 The Regents Of The University Of California Diarylhydantoin compounds
AU2015246137B2 (en) * 2005-05-13 2017-06-15 The Regents Of The University Of California Diarylhydantoin compounds
PT2656841T (pt) 2006-03-27 2016-09-28 Univ California Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
KR101600230B1 (ko) 2006-03-29 2016-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
GB0612428D0 (en) * 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
TW200846338A (en) * 2007-02-01 2008-12-01 Chugai Pharmaceutical Co Ltd Pyridyl imidazolidine derivative having sulfamoyl group, and pharmaceutical use thereof
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EP2220050A2 (en) * 2007-10-26 2010-08-25 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
GB0724342D0 (en) * 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
AU2009239430B2 (en) 2008-04-21 2015-01-22 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
KR20110130439A (ko) 2009-02-24 2011-12-05 메디베이션 프로스테이트 테라퓨틱스 인코퍼레이티드 특정 디아릴히단토인 및 디아릴티오히단토인 화합물
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗***癌的雄性激素受体拮抗剂
US8710086B2 (en) * 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
EP2475647B1 (en) * 2009-09-10 2015-11-04 Suzhou Kintor Pharmaceuticals, Inc. Androgen receptor antagonists and uses thereof
TW201111378A (en) * 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
WO2011044327A1 (en) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
JP5897783B2 (ja) * 2009-12-24 2016-03-30 株式会社ロッテ 抗アンドロゲン剤及び皮脂分泌抑制剤
AU2011204323B2 (en) * 2010-01-07 2013-12-12 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
ES2668380T3 (es) 2010-02-16 2018-05-17 Aragon Pharmaceuticals, Inc. Moduladores de receptores de andrógenos y sus usos
CA2790924C (en) * 2010-02-24 2016-08-02 Medivation Prostate Therapeutics, Inc. Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
GEP20156318B (en) 2011-02-23 2015-07-10 Lupin Ltd Heteroaryl derivatives as alpha7 nachr modulators
BR112013023028B1 (pt) 2011-03-10 2021-09-21 Suzhou Kintor Pharmaceuticals, Inc Composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e formulação farmacêutica tópica
US8921378B2 (en) 2011-04-21 2014-12-30 Orion Corporation Androgen receptor modulating carboxamides
SG11201405239WA (en) 2012-03-06 2014-09-26 Lupin Ltd Thiazole derivatives as alpha 7 nachr modulators
US9604976B2 (en) 2012-03-22 2017-03-28 Spero Gyrase, Inc. Antibacterial compounds
AU2013312587B2 (en) * 2012-09-04 2017-03-16 Jiangsu Hengrui Medicine Co., Ltd. Imidazoline derivatives, preparation methods thereof, and their applications in medicine
SI3305285T1 (sl) 2012-09-26 2021-03-31 Aragon Pharmaceuticals, Inc. Anti-androgeni za zdravljenje proti kastraciji odpornega ne-metastatskega raka
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CN104341351B (zh) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 一种二芳基硫代乙内酰脲衍生物及其应用
WO2015018356A1 (zh) * 2013-08-08 2015-02-12 上海医药集团股份有限公司 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
CZ2014232A3 (cs) * 2014-04-07 2015-10-14 Zentiva, K.S. Způsob výroby enzalutamidu
KR20200052995A (ko) * 2015-01-20 2020-05-15 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
ITUB20151256A1 (it) 2015-05-28 2016-11-28 Olon Spa Processo industriale per la preparazione di enzalutamide
PL3348546T3 (pl) 2015-09-10 2020-09-21 Jiangsu Hengrui Medicine Co., Ltd. Krystaliczna forma inhibitora receptora androgenu i sposób przygotowania
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
CN109422737B (zh) * 2017-08-22 2021-07-30 上海时莱生物技术有限公司 咪唑酮类雄激素受体拮抗剂、其制备方法和用途
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال
CN108314654B (zh) * 2018-03-22 2020-07-03 山东百诺医药股份有限公司 一种用于制备美托咪定的中间体及其制备方法和应用
CN108976171B (zh) * 2018-08-27 2020-06-16 长沙泽达医药科技有限公司 化合物、组合物及其在药物制备中的用途
AU2019404022A1 (en) * 2018-12-19 2021-07-08 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
JP7494181B2 (ja) 2018-12-19 2024-06-03 セルジーン コーポレイション 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法
CN112919984B (zh) * 2021-04-16 2022-03-08 安徽硒无忧现代农业科技有限公司 一种生态化富硒有机营养液及其制备方法
CN114920686B (zh) * 2022-05-20 2023-11-24 山东农业大学 5-(苯磺酰基)-n-哌啶-4-基-2-(三氟甲基)苯磺酰胺盐酸盐的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1543563A1 (de) 1966-01-11 1969-12-11 Bayer Ag Verfahren zur Herstellung von N-Aryl-alpha-aminosaeureestern
FR2060088B1 (zh) 1969-08-08 1974-08-30 Orsymonde
US4035143A (en) 1972-11-04 1977-07-12 Cassella Farbwerke Mainkur Aktiengesellschaft Water-insoluble azo dyestuffs
DE2254017C2 (de) * 1972-11-04 1981-10-29 Cassella Ag, 6000 Frankfurt Wasserunlösliche Azofarbstoffe und Verfahren zu ihrer Herstellung
DE2308044A1 (de) 1973-02-19 1974-08-29 Cassella Farbwerke Mainkur Ag Verfahren zum faerben synthetischer fasermaterialien aus organischen loesungsmitteln
DE2404741C2 (de) 1974-02-01 1985-07-04 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Folien, Überzügen und Formkörpern aus Polyhydantoinen bzw. Polyparabansäuren
JPH0219363A (ja) * 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
GB2308044B (en) * 1995-10-02 2000-03-15 Motorola Ltd Method of decoding punctured codes and apparatus therefor
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
US5741926A (en) 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
WO2004031160A2 (fr) 2002-10-04 2004-04-15 Laboratoires Fournier S.A. Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete
US7354933B2 (en) 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds

Also Published As

Publication number Publication date
CN101676270A (zh) 2010-03-24
KR20070106969A (ko) 2007-11-06
WO2006028226A1 (ja) 2006-03-16
EP1790640A1 (en) 2007-05-30
US8470829B2 (en) 2013-06-25
EP1790640A4 (en) 2009-07-29
AU2005280908A1 (en) 2006-03-16
JPWO2006028226A1 (ja) 2008-05-08
CA2579886A1 (en) 2006-03-16
CN101048381A (zh) 2007-10-03
JP4989227B2 (ja) 2012-08-01
US20110306615A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
TW200621723A (en) Novel imidazolidine derivative and use thereof
WO2001038324A3 (en) Imidazole derivatives and their use as raf kinase inhibitors
MY107756A (en) Piperazine derivatives.
RS20050311A (en) Selected cgrp antagonists,method for production and use thereof as medicament
RS20050329A (en) Selected cgrp antagonists,method for production and use thereof as medicament
NO20063549L (no) (3-okso-3,4-dihydro-quinoksalin-2-yl-amino)-Benzamidderivater og relatert forbindelse som glykogenfosforylaseinhibitorer for behandling av diabetes og fedme
NO20050065L (no) Kjemiske forbindelser
ATE368655T1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
GB9922173D0 (en) Chemical compounds
GEP20074198B (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivates and their use as antibacterials
MY140572A (en) Quinazolinone derivatives as parp inhibitors
NO20064166L (no) Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
HRP20080113T3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
KR20050085991A (en) Compounds exhibiting thrombopoietin receptor agonism
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
EA199800603A1 (ru) Производные 1-(1,2-дизамещенный пиперидинил)-4-(конденсированный имидазол)-пиперидина
IL163625A0 (en) Alkoxy-pyridine derivatives and pharmaceutical compositions containing the same
ATE497948T1 (de) Bicyclische verbindungen
MXPA05013631A (es) Derivado heterociclico de metilsulfona.
NO20055515L (no) 7-azaindoler og deres anvendelse som terapeutiske midler
EP0997462A4 (en) NOVEL NAPHTHYRIDINE DERIVATIVES OR THEIR SALTS
MXPA04009421A (es) Compuestos de tiazol-2-ilimina como inhibidores de la pde-7.
DE60230781D1 (en) Reverse hydroxamsäurederivate